Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Precision medicine in Ewing sarcoma: a translational point of view.

Gargallo P, Juan A, Yáñez Y, Dolz S, Segura V, Castel V, Cañete A.

Clin Transl Oncol. 2020 Feb 5. doi: 10.1007/s12094-020-02298-7. [Epub ahead of print] Review.

PMID:
32026343
2.

Publisher Correction: Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.

Juan Ribelles A, Barberá S, Yáñez Y, Gargallo P, Segura V, Juan B, Noguera R, Piqueras M, Fornés-Ferrer V, Font de Mora J, Cañete A, Castel V.

Sci Rep. 2020 Jan 31;10(1):1914. doi: 10.1038/s41598-020-58428-2.

3.

Metabolomic profiling in neuroblastoma.

Quintás G, Yáñez Y, Gargallo P, Juan Ribelles A, Cañete A, Castel V, Segura V.

Pediatr Blood Cancer. 2020 Mar;67(3):e28113. doi: 10.1002/pbc.28113. Epub 2019 Dec 4.

PMID:
31802629
4.

Li-Fraumeni syndrome heterogeneity.

Gargallo P, Yáñez Y, Segura V, Juan A, Torres B, Balaguer J, Oltra S, Castel V, Cañete A.

Clin Transl Oncol. 2019 Nov 5. doi: 10.1007/s12094-019-02236-2. [Epub ahead of print] Review.

PMID:
31691207
5.

Review: Ewing Sarcoma Predisposition.

Gargallo P, Yáñez Y, Juan A, Segura V, Balaguer J, Torres B, Oltra S, Castel V, Cañete A.

Pathol Oncol Res. 2019 Oct 26. doi: 10.1007/s12253-019-00765-3. [Epub ahead of print] Review.

PMID:
31656020
6.

Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study.

Morini M, Cangelosi D, Segalerba D, Marimpietri D, Raggi F, Castellano A, Fruci D, de Mora JF, Cañete A, Yáñez Y, Viprey V, Corrias MV, Carlini B, Pezzolo A, Schleiermacher G, Mazzocco K, Ladenstein R, Sementa AR, Conte M, Garaventa A, Burchill S, Luksch R, Bosco MC, Eva A, Varesio L.

Cancers (Basel). 2019 Sep 30;11(10). pii: E1476. doi: 10.3390/cancers11101476.

7.

Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages.

Juan Ribelles A, Barberá S, Yáñez Y, Gargallo P, Segura V, Juan B, Noguera R, Piqueras M, Fornés-Ferrer V, de Mora JF, Cañete A, Castel V.

Sci Rep. 2019 Sep 24;9(1):13806. doi: 10.1038/s41598-019-50327-5. Erratum in: Sci Rep. 2020 Jan 31;10(1):1914.

8.

Retinoblastoma: towards an earlier diagnosis.

Gargallo P, Oltra JS, Yáñez Y, Segura V, Balaguer J, Cañete A.

Arch Soc Esp Oftalmol. 2018 Sep;93(9):439-443. doi: 10.1016/j.oftal.2018.05.003. Epub 2018 Jun 19. English, Spanish.

PMID:
29929761
9.

Letter to the Editor.

Castel V, Cañete A, Calabria I, Cervera J, Dolz S, Escobar P, Font de Mora J, Gargallo P, Llavador G, Pedrola L, Yañez Y, Zuñiga A.

Clin Transl Oncol. 2018 Dec;20(12):1626-1627. doi: 10.1007/s12094-018-1889-1. Epub 2018 May 28. No abstract available.

PMID:
29808413
10.

[Li-Fraumeni: Will the detection in families increase the survival of its members?]

Gargallo P, Segura V, Yáñez Y, Balaguer J, Cañete A.

An Pediatr (Barc). 2019 Jan;90(1):54-55. doi: 10.1016/j.anpedi.2018.03.009. Epub 2018 Apr 17. Spanish. No abstract available.

11.

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.

Corrias MV, Parodi S, Tchirkov A, Lammens T, Vicha A, Pasqualini C, Träger C, Yáñez Y, Dallorso S, Varesio L, Luksch R, Laureys G, Valteau-Couanet D, Canete A, Pöetschger U, Ladenstein R, Burchill SA.

Pediatr Blood Cancer. 2018 Jul;65(7):e27052. doi: 10.1002/pbc.27052. Epub 2018 Mar 30.

12.

Epigenetics and Oxidative Stress in Aging.

Guillaumet-Adkins A, Yañez Y, Peris-Diaz MD, Calabria I, Palanca-Ballester C, Sandoval J.

Oxid Med Cell Longev. 2017;2017:9175806. doi: 10.1155/2017/9175806. Epub 2017 Jul 20. Review.

13.

TIAM1 variants improve clinical outcome in neuroblastoma.

Sanmartín E, Yáñez Y, Fornés-Ferrer V, Zugaza JL, Cañete A, Castel V, Font de Mora J.

Oncotarget. 2017 Jul 11;8(28):45286-45297. doi: 10.18632/oncotarget.16787.

14.

Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma.

Torres-Vega E, Durán-Moreno M, Sánchez Del Pino M, Yáñez Y, Cañete A, Castel V, López-Cuevas R, Vílchez JJ, Dalmau J, Graus F, García Verdugo JM, Bataller L.

J Neuroimmunol. 2016 Aug 15;297:98-102. doi: 10.1016/j.jneuroim.2016.05.015. Epub 2016 May 25.

PMID:
27397082
15.

TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.

Yáñez Y, Hervás D, Grau E, Oltra S, Pérez G, Palanca S, Bermúdez M, Márquez C, Cañete A, Castel V.

J Cancer Res Clin Oncol. 2016 Mar;142(3):573-80. doi: 10.1007/s00432-015-2054-7. Epub 2015 Oct 24.

PMID:
26498952
16.

Two independent epigenetic biomarkers predict survival in neuroblastoma.

Yáñez Y, Grau E, Rodríguez-Cortez VC, Hervás D, Vidal E, Noguera R, Hernández M, Segura V, Cañete A, Conesa A, Font de Mora J, Castel V.

Clin Epigenetics. 2015 Feb 27;7:16. doi: 10.1186/s13148-015-0054-8. eCollection 2015.

17.

Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor.

Hämmerle B, Yañez Y, Palanca S, Cañete A, Burks DJ, Castel V, Font de Mora J.

PLoS One. 2013 Oct 7;8(10):e76761. doi: 10.1371/journal.pone.0076761. eCollection 2013.

18.

New prognostic markers in neuroblastoma.

Navarro S, Piqueras M, Villamón E, Yáñez Y, Balaguer J, Cañete A, Noguera R.

Expert Opin Med Diagn. 2012 Nov;6(6):555-67. doi: 10.1517/17530059.2012.704018. Epub 2012 Jul 11.

PMID:
23480837
19.

Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.

Yáñez Y, Grau E, Oltra S, Cañete A, Martínez F, Orellana C, Noguera R, Palanca S, Castel V.

J Cancer Res Clin Oncol. 2011 Aug;137(8):1263-72. doi: 10.1007/s00432-011-0997-x. Epub 2011 Jun 25.

PMID:
21706131
20.

Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease.

Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, Noguera R, Hernandez M, Bermúdez JD, Castel V.

Mol Carcinog. 2011 Mar;50(3):153-62. doi: 10.1002/mc.20700. Epub 2010 Nov 23.

PMID:
21104989
21.

Epigenetic alterations in disseminated neuroblastoma tumour cells: influence of TMS1 gene hypermethylation in relapse risk in NB patients.

Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, Noguera R, Hernandez M, Bermúdez JD, Castel V.

J Cancer Res Clin Oncol. 2010 Sep;136(9):1415-21. doi: 10.1007/s00432-010-0796-9. Epub 2010 Feb 7.

PMID:
20140741
22.

Neuroblastoma in adolescents: genetic and clinical characterisation.

Castel V, Villamón E, Cañete A, Navarro S, Ruiz A, Melero C, Herrero A, Yáñez Y, Noguera R.

Clin Transl Oncol. 2010 Jan;12(1):49-54. doi: 10.1007/s12094-010-0466-z.

PMID:
20080471
23.

RSC mobilizes nucleosomes to improve accessibility of repair machinery to the damaged chromatin.

Shim EY, Hong SJ, Oum JH, Yanez Y, Zhang Y, Lee SE.

Mol Cell Biol. 2007 Mar;27(5):1602-13. Epub 2006 Dec 18.

24.

Noise level analysis in buffer rod geometries for ultrasonic sensors.

Garcia-Alvarez J, Yañez Y, Prego JL, Turo A, Chavez JA, Garcia MJ, Salazar J.

Ultrasonics. 2006 Dec 22;44 Suppl 1:e1093-100. Epub 2006 Jun 6.

PMID:
16797654
25.

Effects of severe depression on TOMM performance among disability-seeking outpatients.

Yanez YT, Fremouw W, Tennant J, Strunk J, Coker K.

Arch Clin Neuropsychol. 2006 Feb;21(2):161-5. Epub 2005 Oct 13.

26.

The yeast chromatin remodeler RSC complex facilitates end joining repair of DNA double-strand breaks.

Shim EY, Ma JL, Oum JH, Yanez Y, Lee SE.

Mol Cell Biol. 2005 May;25(10):3934-44.

Supplemental Content

Support Center